Market Mover: Cytokinetics (CYTK) Rises at Midday May 13

Equities Staff  |

Today Cytokinetics Inc (NASDAQ: CYTK) is trading 7.54% up.

The latest price, as of 11:52:38 est, was $40.35. Cytokinetics has climbed $2.89 over the previous day’s close.

394,498 shares have traded hands.

As of the previous close, Cytokinetics has moved YTD 15.86%. The company is set to release earnings on 2022-08-04.

For technical charts, analysis, and more on Cytokinetics visit the company profile.

About Cytokinetics Inc

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

To get more information on Cytokinetics Inc and to follow the company's latest updates, you can visit the company's profile page here: Cytokinetics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold
The Best Laid Plans of Mice and Men — Part I
Bumble Beats First Quarter Estimates, Has Over 3 Million Paying Users
Squarespace Beats Revenue Estimates With Record Q1
BridgeBio Pharma Inks Licensing Deal With Bristol Myers Squibb Worth up to $905 Million
How To Trade in a Bearish Market
AbbVie and Teva Weighing $5 Billion Opioid Lawsuit Settlement



Market Movers

Sponsored Financial Content